Results 31 to 40 of about 6,214,933 (159)

Biofluid Proteomic Biomarker Discovery in a Large Animal Model of CLN2 Neuronal Ceroid Lipofuscinosis [PDF]

open access: yesBiology
CLN2 disease is a fatal lysosomal storage disorder caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1 (TPP1), resulting in progressive neurodegeneration and non-neuronal pathology.
Brandie R. Morgan-Jack   +8 more
doaj   +2 more sources

A needle in a haystack? The impact of a targeted epilepsy gene panel in the identification of a treatable but rapidly progressive metabolic epilepsy: CLN2 disease [PDF]

open access: yesArquivos de Neuro-Psiquiatria
Background Neuronal ceroid lipofuscinoses (NCL) are a group of autosomal recessive, inherited, lysosomal, and neurodegenerative diseases that causes progressive dementia, seizures, movement disorders, language delay/regression, progressive ...
Charles Marques Lourenço   +8 more
doaj   +2 more sources

OCT Biomarkers in Ocular CLN2 Disease in Patients Treated With Intraventricular Enzyme Replacement Therapy [PDF]

open access: yesInvestigative Ophthalmology & Visual Science
Bilateral progressive, symmetrical loss of central retinal thickness (CRT) has been described in neuronal ceroid lipofuscinosis type 2 (CLN2) disease. This study details the pattern of morphological changes underlying CRT loss and disease progression in patients receiving intracerebroventricular (ICV) enzyme replacement therapy (ERT) with cerliponase ...
Huang, Wei Chieh   +6 more
openaire   +3 more sources

Enzyme Replacement Therapy for CLN2 Disease: MRI Volumetry Shows Significantly Slower Volume Loss Compared with a Natural History Cohort. [PDF]

open access: yesAJNR Am J Neuroradiol
BACKGROUND AND PURPOSE: Neuronal ceroid lipofuscinoses (NCL) are a group of neurodegenerative disorders. Recently, enzyme replacement therapy (ERT) was approved for CLN2, a subtype of NCL.
Gaur P   +9 more
europepmc   +2 more sources

Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. [PDF]

open access: yesLancet Child Adolesc Health, 2018
BACKGROUND: Late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease, characterised by rapid psychomotor decline and epilepsy, is caused by deficiency of the lysosomal enzyme tripeptidyl peptidase 1.
Nickel M   +15 more
europepmc   +2 more sources

Antibiotic treatment reveals the contributions of the gut microbiome to CLN2 disease in the central and enteric nervous system [PDF]

open access: yesScientific Reports
The Neuronal Ceroid Lipofuscinoses (NCLs) are fatal inherited lysosomal storage diseases, with pronounced neuron loss in the central nervous system (CNS). Gastrointestinal issues are frequently reported by people with NCLs, although mechanisms underlying
Ewa A. Ziółkowska   +9 more
doaj   +2 more sources

Brain Region–Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease) [PDF]

open access: yesAmerican Journal of Neuroradiology, 2016
Late infantile neuronal ceroid lipofuscinosis (CLN2 disease) is a uniformly fatal lysosomal storage disease resulting from mutations in the CLN2 gene. Our hypothesis was that regional analysis of cortical brain degeneration may identify brain regions that are affected earliest and most severely by the disease.Fifty-two high-resolution 3T MR imaging ...
J.P. Dyke   +12 more
openaire   +3 more sources

A Single-Center Review of Infusion-Associated Reactions in Patients with CLN2 Disease Receiving Cerliponase Alfa

open access: yesBiologics
Background: Cerliponase alfa is an intracerebroventricular (ICV) enzyme replacement therapy (ERT) and the only approved treatment for neuronal ceroid lipofuscinosis type 2 (CLN2) disease.
Rebecca Whiteley   +8 more
doaj   +2 more sources

Inflammatory masquerade features in adult-onset CLN-associated retinal degeneration in a multiethnic Asian cohort [PDF]

open access: yesJournal of Ophthalmic Inflammation and Infection
Purpose To describe the clinical, imaging, and genetic features of non-syndromic neuronal ceroid lipofuscinosis (NCL)-associated retinal degeneration in a multi-ethnic Asian cohort, with particular emphasis on cases that were initially considered in the ...
Srinivasan Sanjay   +9 more
doaj   +2 more sources

Brain transcriptome analysis of a CLN2 mouse model as a function of disease progression [PDF]

open access: yesJournal of Neuroinflammation, 2021
Abstract Background Neuronal ceroid lipofuscinoses, (NCLs or Batten disease) are a group of inherited, early onset, fatal neurodegenerative diseases associated with mutations in 13 genes. All forms of the disease are characterized by lysosomal accumulation of fluorescent storage material, as well as profound ...
Miriam S. Domowicz   +4 more
openaire   +3 more sources

Home - About - Disclaimer - Privacy